+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tinzaparin"

Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User and Distribution Channel - Product Thumbnail Image

Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product, Packaging, Application, End User and Distribution Channel

  • Report
  • October 2022
  • 216 Pages
  • Middle East
From
Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application , and End User, and Geography - Product Thumbnail Image

Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application , and End User, and Geography

  • Report
  • December 2021
  • 191 Pages
  • Global
From
Low Molecular Weight Heparin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - Product Thumbnail Image

Low Molecular Weight Heparin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • Report
  • August 2022
  • 100 Pages
  • Global
From
Low Molecular Weight Heparin Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Low Molecular Weight Heparin Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2022
  • 87 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Tinzaparin is a low molecular weight heparin (LMWH) anticoagulant used in the treatment of cardiovascular diseases. It is a type of anticoagulant that works by preventing the formation of blood clots. Tinzaparin is used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as to prevent the formation of blood clots in patients undergoing certain types of surgery. It is also used to prevent stroke in patients with atrial fibrillation. Tinzaparin is administered by subcutaneous injection and is available in both generic and branded forms. The Tinzaparin market is a rapidly growing segment of the cardiovascular drugs market. It is expected to witness strong growth in the coming years, driven by the increasing prevalence of cardiovascular diseases, the growing demand for anticoagulants, and the increasing availability of generic versions of Tinzaparin. Some of the major companies operating in the Tinzaparin market include Sanofi, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Bayer, and Daiichi Sankyo. Show Less Read more